Dr Reddy's Laboratories Ltd has received a Form 483 from the US Food and Drug Administration (FDA) following an inspection of its Srikakulam facility in Andhra Pradesh. The regulatory document listed three observations.

A Form 483 is issued by the FDA to facility management at the conclusion of an inspection when investigators observe conditions that may constitute violations of the Federal Food, Drug, and Cosmetic Act or related regulations. The observations are preliminary and do not represent the agency's final determination of compliance. Companies that receive a Form 483 typically respond in writing with corrective and preventive action plans, and the FDA may classify the inspection outcome after reviewing those responses.

FDA inspections of Indian manufacturing facilities are closely watched by investors and industry analysts, as the United States is the largest export market for India's pharmaceutical sector. Observations on a Form 483 can range from procedural or documentation issues to more significant compliance concerns, and outcomes generally depend on the nature of the observations and the adequacy of a company's remediation efforts.

Shares of Dr Reddy's Laboratories ended at ₹1,143.20 on the Bombay Stock Exchange (BSE), up ₹7.55, or 0.66%.

Dr Reddy's Laboratories, headquartered in Hyderabad, India, is a global pharmaceutical company that develops and markets active pharmaceutical ingredients, generic drugs, and proprietary medicines. The company operates multiple manufacturing facilities across India and internationally, serving markets in North America, Europe, and emerging economies.